Verrica Pharmaceuticals Inc
VRCA5.716USD
+0.076+1.35%
Market hours （ET）Quotes delayed by 15 min
524.71MMarket Cap
LossP/E TTM
More Details of Verrica Pharmaceuticals Inc Company
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: YCANTH, VP-315 and VP-103. YCANTH is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are also developing YCANTH for potential follow-on indications for the treatment of common warts and external genital warts. In addition, the Company is also developing YCANTH for the treatment of external genital warts, or external genital warts EGW. Its second candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, non-metastatic melanoma, and non-metastatic Merkel cell carcinoma. VP-103, a second cantharidin based drug device combination for the potential treatment of plantar warts.
Company Info
Ticker SymbolVRCA
Company nameVerrica Pharmaceuticals Inc
IPO dateJun 15, 2018
CEODr. Jayson Rieger
Number of employees71
Security typeOrdinary Share
Fiscal year-endJun 15
Address44 West Gay Street
CityWEST CHESTER
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code19380
Phone14844533300
Websitehttps://verrica.com/
Ticker SymbolVRCA
IPO dateJun 15, 2018
CEODr. Jayson Rieger
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Jayson Rieger
Dr. Jayson Rieger
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
88.99K
+50.90%
Mr. David Zawitz
Mr. David Zawitz
Chief Operating Officer
Chief Operating Officer
11.00K
--
Dr. Diem Nguyen, Ph.D.
Dr. Diem Nguyen, Ph.D.
Independent Director
Independent Director
10.00
--
Dr. Gavin Corcoran
Dr. Gavin Corcoran
Independent Director
Independent Director
2.00
--
Dr. Noah L. Rosenberg, M.D.
Dr. Noah L. Rosenberg, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Lawrence Eichenfield, M.D.
Dr. Lawrence Eichenfield, M.D.
Independent Director
Independent Director
--
--
Mr. John J. Kirby
Mr. John J. Kirby
Interim Chief Financial Officer, Interim Principal Financial Officer
Interim Chief Financial Officer, Interim Principal Financial Officer
--
--
Mr. Paul B. Manning
Mr. Paul B. Manning
Chairman of the Board
Chairman of the Board
--
--
Mr. Mark A. Prygocki, Sr.
Mr. Mark A. Prygocki, Sr.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Jayson Rieger
Dr. Jayson Rieger
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
88.99K
+50.90%
Mr. David Zawitz
Mr. David Zawitz
Chief Operating Officer
Chief Operating Officer
11.00K
--
Dr. Diem Nguyen, Ph.D.
Dr. Diem Nguyen, Ph.D.
Independent Director
Independent Director
10.00
--
Dr. Gavin Corcoran
Dr. Gavin Corcoran
Independent Director
Independent Director
2.00
--
Dr. Noah L. Rosenberg, M.D.
Dr. Noah L. Rosenberg, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Lawrence Eichenfield, M.D.
Dr. Lawrence Eichenfield, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, May 16
Updated: Fri, May 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Manning (Paul B.)
53.85%
Caligan Partners, LP
9.72%
Armistice Capital LLC
9.26%
BKB Growth Investments LLC
6.46%
Boothbay Fund Management, LLC
3.04%
Other
17.67%
Shareholders
Shareholders
Proportion
Manning (Paul B.)
53.85%
Caligan Partners, LP
9.72%
Armistice Capital LLC
9.26%
BKB Growth Investments LLC
6.46%
Boothbay Fund Management, LLC
3.04%
Other
17.67%
Shareholder Types
Shareholders
Proportion
Individual Investor
57.67%
Hedge Fund
19.53%
Investment Advisor
6.74%
Corporation
6.74%
Investment Advisor/Hedge Fund
5.58%
Research Firm
0.28%
Venture Capital
0.06%
Bank and Trust
0.04%
Pension Fund
0.01%
Other
3.35%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
182
8.94M
96.65%
+3.24M
2025Q1
194
69.94M
75.99%
+19.16M
2024Q4
191
70.39M
77.72%
+35.42M
2024Q3
179
29.67M
67.28%
-5.27M
2024Q2
173
33.68M
79.75%
-1.13M
2024Q1
171
34.51M
82.01%
-2.46M
2023Q4
170
35.04M
83.66%
+1.56M
2023Q3
172
32.74M
78.91%
-2.85M
2023Q2
169
31.35M
77.69%
+2.98M
2023Q1
171
29.74M
73.94%
+2.67M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Manning (Paul B.)
31.38M
33.93%
+17.53M
+126.54%
Nov 26, 2024
Caligan Partners, LP
8.99M
9.72%
+1.56M
+21.04%
Mar 31, 2025
Armistice Capital LLC
8.57M
9.26%
-353.60K
-3.96%
Mar 31, 2025
BKB Growth Investments LLC
5.98M
6.46%
+5.98M
--
Nov 22, 2024
Boothbay Fund Management, LLC
2.81M
3.04%
+220.30K
+8.52%
Mar 31, 2025
The Vanguard Group, Inc.
2.36M
2.55%
+481.41K
+25.61%
Mar 31, 2025
Stalfort (John A)
1.87M
2.03%
+238.09K
+14.56%
Apr 01, 2025
BlackRock Institutional Trust Company, N.A.
1.12M
1.22%
+32.58K
+2.98%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.02M
1.1%
+541.22K
+113.40%
Mar 31, 2025
Rieger (Jayson)
889.88K
0.96%
+300.19K
+50.91%
Apr 01, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
0%
Simplify Propel Opportunities ETF
0%
iShares Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
Simplify Propel Opportunities ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
